Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Solid fundamentals underpinning a recovery at St James's Place, says Berenberg

(Sharecast News) - Berenberg hiked its price target on St James's Place on Tuesday to 1,300p from 850p to reflect the high level of visibility that it has on the company's 2030 targets and its conviction that the group can capitalise on the structural opportunity. The bank said the price target values SJP on 10x its FY29 estimated earnings per share.

Berenberg said that solid fundamentals are underpinning a recovery.

"St. James's Place (SJP) has recovered its poise, in our view," it said. "Annualised Q125 net inflows of 3.8% marked an acceleration from 3.3% in Q424 and the low of 1.7% a year ago.

"Despite the challenging regulatory and market backdrop, the underlying business has remained fundamentally sound."

It also said that higher-for-longer interest rates could continue to be a hurdle to clients committing to new investment, while a sharper focus on productivity may initially weigh on adviser and client numbers.

"However, management's 2030 target to double the underlying cash result only assumes net inflows of 2-3% per year.

"This is not only underpinned by the structural opportunity, but we think that there is upside to this if investment helps SJP to capture a larger wallet share."

Berenberg maintained its 'buy' rating on the stock.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.